search
Back to results

Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease

Primary Purpose

Obesity, Cardiovascular Disease

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Lifestyle-based physical activity
Sponsored by
Nemours Children's Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Obesity

Eligibility Criteria

14 Years - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Obese: BMI ≥30 kg/m2
  • Lean (controls): BMI ≤ 25 kg/m2) age 14 to 18 years and Tanner stage matched
  • Ability to understand and cooperate with the procedures
  • Signed informed consent from subjects and parents

Exclusion Criteria:

  • Medications such as Beta-adrenergic blockers, steroids and other drugs known to affect protein metabolism
  • Heart disease
  • Chronic liver disease
  • Chronic renal disease
  • Active malignancy
  • Alcoholism or drug abuse
  • Anemia
  • Inter-current illness over the 7 days before the study
  • Surgery in the past 3 months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Intervention

    Control

    Arm Description

    12 weeks of lifestyle-based physical activity intervention

    12 weeks of no intervention

    Outcomes

    Primary Outcome Measures

    Protein turnover
    Stable isotope mass spectrometry
    Fractional synthesis rate of fibrinogen
    Stable isotope mass spectrometry
    Fibrinogen
    Plasma concentration measured by nephelometry

    Secondary Outcome Measures

    Fat mass
    Dual-energy X-ray absorptiometry (DEXA)
    Fat free mass
    Dual-energy X-ray absorptiometry (DEXA)

    Full Information

    First Posted
    November 19, 2015
    Last Updated
    October 13, 2022
    Sponsor
    Nemours Children's Clinic
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02613741
    Brief Title
    Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease
    Official Title
    Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2001 (Actual)
    Primary Completion Date
    January 2004 (Actual)
    Study Completion Date
    December 2020 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Nemours Children's Clinic

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Since obesity and plasma fibrinogen levels are important CVD risk factors in the adults, and since childhood obesity is a major risk factor for adult obesity and also because it is not established whether or not this is due to an increase in the FSR of fibrinogen, the investigators set up the studies with the following specific aims: To investigate the metabolism of fibrinogen and VLDL apoB-100, CVD risk factors, in childhood obesity by measuring their fractional synthetic rate (FSR) compared to lean age and sex matched controls To determine the outcome of a three month non-pharmacological intervention (physical exercise combined with controlled diet) to reduce weight on the FSR of fibrinogen and apoB-100 To determine the relationship between FSR of fibrinogen and IL-6 in obese children and its potential implications on CVD before and after the non-pharmacological intervention To determine other CVD risk factors, PAI-1 levels, D-Dimer concentration, homocysteine, insulin, free fatty acid, HDL & LDL cholesterol and blood pressure in response to weight reduction (as consequence of a combined program of diet and exercise).
    Detailed Description
    A. SPECIFIC AIMS: Evidence from the literature suggests that: childhood onset of obesity increases the risk of obesity and cardiovascular disease (CVD) in adulthood; plasma fibrinogen and apolipoprotein B-100 (apoB-100) levels are elevated in obesity; elevated levels of plasma fibrinogen and apolipoprotein B-100 (apoB-100) are major independent risk factors for CVD in adults; raised plasma fibrinogen levels in obese children and/adolescents could be a major factor responsible for CVD morbidity and mortality in adulthood; a low level of physical activity is associated with a high level of plasma fibrinogen in adults; physical training and controlled diet have been proved to be non-pharmacological ways to improve hemostatic function in adults, thereby reducing heart disease risk. Despite these evidences the mechanism of these changes remain unclear. A better understanding of the mechanism of these changes will lead to more directed therapies to reduce these risk factors early in life. The increased plasma concentrations of fibrinogen (and/or other proteins) is decided by the equilibrium between two dynamic processes in the body, namely, synthesis and degradation rates of these proteins. Therefore, elevated levels of fibrinogen must be a consequence of: increased fibrinogen synthesis; decreased fibrinogen degradation or a contribution of both. For designing effective therapies it is important to know, whether the increased concentration of plasma fibrinogen is due to increased synthesis or decreased degradation or both. Using stable isotope mass spectrometry techniques it is possible to measure the synthesis rates of proteins in vivo in humans. Yet until now there are no reports on the direct measurement of FSR of fibrinogen and/or apoB-100 in childhood obesity, important CVD risk factors. The direct measurement of degradation rates of proteins in vivo in humans, however, is not easily done. Few studies have reported changes in the concentrations of fibrinolytic markers such as plasminogen activator inhibitor-1 (PAI-1) and D-Dimer in obesity. This, however, accounts for only a small fraction of the elevated levels of plasma fibrinogen in childhood obesity. On the other hand recent preliminary results in three subjects from our lab show that fibrinogen synthesis rate is substantially higher (more than two times) in obese adolescent girls Vs lean controls (please see results under "Preliminary results" below). Pro-inflammatory cytokines, particularly interleukin-6 (IL-6), are known to play an important role in the regulation of acute phase reactive proteins associated with inflammation, including fibrinogen. A direct link between IL-6 and increased FSR of plasma fibrinogen in childhood obesity and CVD, however, is unknown. Also, other mechanisms involving insulin resistance and free fatty acid/albumin ratio are also equally plausible for the increased synthesis of fibrinogen in obesity and CVD. Therefore, it is important to understand and establish the relationship between increased FSR of fibrinogen and these regulating factors in this study for two reasons: to better design effective therapies based on these results and to further understand the pathophysiology of these changes in CVD and obesity. The overall purpose of the proposed studies is therefore: to expand on our preliminary data and establish the observation of increased fibrinogen synthesis rate (in three subjects) in childhood obesity to understand the relationship between increased FSR of fibrinogen and changes IL-6, insulin and glucose levels and free fatty acid (FFA) levels and FFA/albumin ratio in obese vs lean children to study the effect of a non-pharmacological intervention program for three months (12 weeks), that involves weight reduction due to exercise and controlled diet on fibrinogen, apoB-100 and other cardiovascular risk factors and their relationship to changes in IL-6 levels, insulin/glucose ratio (a measure of insulin resistance), FFA/albumin ratio. The proposed grant will use in vivo stable isotope (non-radioactive) dilution techniques, to test the following hypothesis: Hypotheses: higher rates of synthesis of fibrinogen and apoB-100 contribute substantially to their elevated levels in obese children; plasma fibrinogen and apoB-100 concentration and synthesis decrease by non-pharmacological intervention to reduce weight, that involves regular physical exercise and controlled diet; IL-6 and/or insulin resistance are important mechanistic links between increased plasma fibrinogen FSR and increased CVD risk and obesity and the non-pharmacological intervention program modulates other CVD risk factors such as PAI-1, D-Dimer, homocysteine, free fatty acids, insulin, glucose, HDL and LDL cholesterol levels and IL-6 concentrations along with fibrinogen synthesis. Summary of Specific Aims Since obesity and plasma fibrinogen levels are important CVD risk factors in the adults, and since childhood obesity is a major risk factor for adult obesity and also because it is not established whether or not this is due to an increase in the FSR of fibrinogen, the investigators set up the studies with the following specific aims: To investigate the metabolism of fibrinogen and VLDL apoB-100, CVD risk factors, in childhood obesity by measuring their fractional synthetic rate (FSR) compared to lean age and sex matched controls To determine the outcome of a three month non-pharmacological intervention (physical exercise combined with controlled diet) to reduce weight on the FSR of fibrinogen and apoB-100 To determine the relationship between FSR of fibrinogen and IL-6 in obese children and its potential implications on CVD before and after the non-pharmacological intervention To determine other CVD risk factors, PAI-1 levels, D-Dimer concentration, homocysteine, insulin, free fatty acid, HDL & LDL cholesterol and blood pressure in response to weight reduction (as consequence of a combined program of diet and exercise).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Obesity, Cardiovascular Disease

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    21 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention
    Arm Type
    Experimental
    Arm Description
    12 weeks of lifestyle-based physical activity intervention
    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    12 weeks of no intervention
    Intervention Type
    Other
    Intervention Name(s)
    Lifestyle-based physical activity
    Intervention Description
    Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
    Primary Outcome Measure Information:
    Title
    Protein turnover
    Description
    Stable isotope mass spectrometry
    Time Frame
    12 weeks
    Title
    Fractional synthesis rate of fibrinogen
    Description
    Stable isotope mass spectrometry
    Time Frame
    12 weeks
    Title
    Fibrinogen
    Description
    Plasma concentration measured by nephelometry
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Fat mass
    Description
    Dual-energy X-ray absorptiometry (DEXA)
    Time Frame
    12 weeks
    Title
    Fat free mass
    Description
    Dual-energy X-ray absorptiometry (DEXA)
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    14 Years
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Obese: BMI ≥30 kg/m2 Lean (controls): BMI ≤ 25 kg/m2) age 14 to 18 years and Tanner stage matched Ability to understand and cooperate with the procedures Signed informed consent from subjects and parents Exclusion Criteria: Medications such as Beta-adrenergic blockers, steroids and other drugs known to affect protein metabolism Heart disease Chronic liver disease Chronic renal disease Active malignancy Alcoholism or drug abuse Anemia Inter-current illness over the 7 days before the study Surgery in the past 3 months
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Babu Balagopal, PhD
    Organizational Affiliation
    Nemours Children's Clinic
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    14513074
    Citation
    Balagopal P, Bayne E, Sager B, Russell L, Patton N, George D. Effect of lifestyle changes on whole-body protein turnover in obese adolescents. Int J Obes Relat Metab Disord. 2003 Oct;27(10):1250-7. doi: 10.1038/sj.ijo.0802388.
    Results Reference
    result
    PubMed Identifier
    15756217
    Citation
    Balagopal P, George D, Patton N, Yarandi H, Roberts WL, Bayne E, Gidding S. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr. 2005 Mar;146(3):342-8. doi: 10.1016/j.jpeds.2004.11.033.
    Results Reference
    result
    PubMed Identifier
    16131584
    Citation
    Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents. J Clin Endocrinol Metab. 2005 Nov;90(11):6192-7. doi: 10.1210/jc.2004-2427. Epub 2005 Aug 30.
    Results Reference
    result
    PubMed Identifier
    17341558
    Citation
    Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007 May;92(5):1971-4. doi: 10.1210/jc.2006-2712. Epub 2007 Mar 6.
    Results Reference
    result
    PubMed Identifier
    18507721
    Citation
    Balagopal P, George D, Sweeten S, Mann KJ, Yarandi H, Mauras N, Vaughan DE. Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D-dimer and fibrinolytic balance to physical activity-based intervention in obese children. J Thromb Haemost. 2008 Aug;6(8):1296-303. doi: 10.1111/j.1538-7836.2008.03037.x. Epub 2008 May 26.
    Results Reference
    result
    PubMed Identifier
    20094040
    Citation
    Balagopal PB, Gidding SS, Buckloh LM, Yarandi HN, Sylvester JE, George DE, Funanage VL. Changes in circulating satiety hormones in obese children: a randomized controlled physical activity-based intervention study. Obesity (Silver Spring). 2010 Sep;18(9):1747-53. doi: 10.1038/oby.2009.498. Epub 2010 Jan 21.
    Results Reference
    result
    PubMed Identifier
    23415619
    Citation
    Lovely R, Hossain J, Ramsey JP, Komakula V, George D, Farrell DH, Balagopal PB. Obesity-related increased gamma' fibrinogen concentration in children and its reduction by a physical activity-based lifestyle intervention: a randomized controlled study. J Pediatr. 2013 Aug;163(2):333-8. doi: 10.1016/j.jpeds.2013.01.004. Epub 2013 Feb 14.
    Results Reference
    result
    PubMed Identifier
    34286837
    Citation
    Cosentino RG, Churilla JR, Josephson S, Molle-Rios Z, Hossain MJ, Prado WL, Balagopal PB. Branched-chain Amino Acids and Relationship With Inflammation in Youth With Obesity: A Randomized Controlled Intervention Study. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3129-3139. doi: 10.1210/clinem/dgab538.
    Results Reference
    derived

    Learn more about this trial

    Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease

    We'll reach out to this number within 24 hrs